Inhibrx (Nasdaq:INBX) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

INBX Panoramica delle azioni

A clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates.

INBX analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 59.66% all'anno

Analisi del rischio

Ha meno di 1 anno di pista di cassa

Non ha entrate significative ( $2M )

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Gli azionisti sono stati diluiti nell'ultimo anno

Inhibrx, Inc. Concorrenti

Syndax Pharmaceuticals

NasdaqGS:SNDX

US$1.7b

Keros Therapeutics

NasdaqGM:KROS

US$1.7b

AnaptysBio

NasdaqGS:ANAB

US$1.0b

Perspective Therapeutics

NYSEAM:CATX

US$909.6m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Inhibrx
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$34.11
Massimo di 52 settimane	US$39.79
Minimo di 52 settimane	US$14.31
Beta	2.88
1Variazione di 1 mese	-0.55%
Variazione a 3 mesi	-6.42%
Variazione di 1 anno	38.66%
3Variazione a 3 anni	55.97%
Variazione a 5 anni	n/a
Variazione dall'IPO	65.34%

Notizie e aggiornamenti recenti

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Jun 07

Recent updates

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Mar 23

Rendimenti per gli azionisti

	INBX	US Biotechs	US Mercato
7D	-0.09%	5.3%	4.9%
1Y	38.7%	15.7%	25.6%

Ritorno vs Industria: INBX ha superato il US Biotechs che ha restituito 15.7 % nell'ultimo anno.

Rendimento vs Mercato: INBX ha superato il mercato US che ha restituito 25.6 % nell'ultimo anno.

Volatilità dei prezzi

Is INBX's price volatile compared to industry and market?
INBX volatility
INBX Average Weekly Movement	1.4%
Biotechs Industry Average Movement	10.6%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.2%

Prezzo delle azioni stabile: INBX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di INBX è diminuita da 8% a 1% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2009	169	Mark Lappe	inhibrx.com

Inhibrx, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Inhibrx con la sua capitalizzazione di mercato?
INBX statistiche fondamentali
Capitalizzazione di mercato	US$1.79b
Guadagni(TTM)	-US$271.15m
Ricavi(TTM)	US$1.78m

1,002x

Rapporto P/S

-6.6x

Rapporto P/E

INBX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
INBX Conto economico (TTM)
Ricavi	US$1.78m
Costo del fatturato	US$218.11m
Profitto lordo	-US$216.32m
Altre spese	US$54.83m
Guadagni	-US$271.15m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-5.17
Margine lordo	-12,132.47%
Margine di profitto netto	-15,207.80%
Rapporto debito/patrimonio netto	1,799.9%

Come si è comportato INBX nel lungo periodo?

Vedi performance storica e confronto

INBX Panoramica delle azioni

Premi

Analisi del rischio

Inhibrx, Inc. Concorrenti

NasdaqGS:SNDX

US$1.7b

NasdaqGM:KROS

US$1.7b

NasdaqGS:ANAB

US$1.0b

NYSEAM:CATX

US$909.6m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Inhibrx Files Form 15

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.

Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Recent updates

Inhibrx Files Form 15

Inhibrx: Continued Advancement Even After INBRX-101 Sale To Sanofi

Aventis Inc. completed the acquisition of Inhibrx, Inc. (NasdaqGM:INBX) from a group of shareholders.

Inhibrx, Inc.(NasdaqGM:INBX) dropped from NASDAQ Biotechnology Index

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Two Separate Complaints with Nearly Identical Claims Filed in Supreme Court of State of New York, County of New York Against Inhibrx, Inc

Is Inhibrx (NASDAQ:INBX) Using Debt Sensibly?

First quarter 2024 earnings released: US$1.44 loss per share (vs US$1.12 loss in 1Q 2023)

Executive VP & CFO notifies of intention to sell stock

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Price target decreased by 20% to US$35.50

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Aventis Inc. entered into a definitive agreement to acquire Inhibrx, Inc. (NasdaqGM:INBX) for $1.4 billion.

Consensus revenue estimates decrease by 22%, EPS upgraded

Consensus revenue estimates increase by 308%, EPS downgraded

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: US$1.10 loss per share (vs US$0.90 loss in 3Q 2022)

Inhibrx, Inc. Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma

Inhibrx, Inc. announced that it has received $200.000633 million in funding

Inhibrx, Inc. announced that it expects to receive $199.999961 million in funding

Consensus revenue estimates increase by 26%

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$1.08 loss per share (vs US$0.97 loss in 2Q 2022)

Inhibrx, Inc. Grants Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus revenue estimates fall by 85%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus forecasts updated

Inhibrx, Inc. Updates Efficacy and Safety Data from Ongoing Phase 1 INBRX-109 Expansion Cohorts for the Treatment of Chondrosarcoma

Consensus revenue estimates increase by 42%

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Founder & Chief Scientific Officer notifies of intention to sell stock

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Inhibrx down 8% after announcing webcast for pathway for rare disease candidate

Founder & Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Founder & Chief Scientific Officer notifies of intention to sell stock

Inhibrx, Inc. Announces Completion of Phase 1 Combination Dose Escalation for INBRX-105

Inhibrx: Potential To Move To Registration Study With INBRX-101

High number of new and inexperienced directors

INBRX-101 Shows Favorable Safety Profile in Patients with Alpha-1 Antitrypsin Deficiency and Demonstrates Potential to Achieve Normal Functional Alpha-1 Antitrypsin Levels with Monthly Dosing

Consensus revenue estimates fall by 17%

Inhibrx, Inc. to Host Webcast Presentation of Topline Results from the Phase 1 Trial of INBRX-101, its Optimized Recombinant Human AAT-Fc Protein for the Treatment of Alpha-1 Antitrypsin Deficiency

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Price target decreased to US$49.67

Inhibrx, Inc. Announces Formation of A Scientific Advisory Board for Its INBRX-101 program

Inhibrx, Inc., Annual General Meeting, May 25, 2022

Inhibrx, Inc. (NASDAQ:INBX) Shares Could Be 38% Below Their Intrinsic Value Estimate

Price target decreased to US$49.67